Effects of mycophenolate mofetil on the expression of monocyte chemoattractant protein-1 and fibronectin in high glucose cultured human mesangial cells

Genetics and Molecular Research

Volumn 13, Issue 2, 2014, Pages 3154-3161

  Chen, F Q ^a   Wang, Q Y ^a   Wei, G Z ^b   Ma, X Y ^a   Ma, D W ^a   Deng, W W ^a   Sun, W B ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Shenyang Orthopedics Hospital   (China)

Author keywords

Diabetic nephropathy; Fibronectin; Human mesangial cells; Monocyte chemoattractant protein 1; Mycophenolate mofetil

Indexed keywords

FIBRONECTIN; GLUCOSE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; CULTURE MEDIUM; MYCOPHENOLIC ACID;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MESANGIUM CELL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CELL CULTURE; CULTURE MEDIUM; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENE EXPRESSION REGULATION; KIDNEY; METABOLISM; PATHOLOGY;

CELLS, CULTURED; CHEMOKINE CCL2; CULTURE MEDIA; DIABETIC NEPHROPATHIES; FIBRONECTINS; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; KIDNEY; MESANGIAL CELLS; MYCOPHENOLIC ACID;

EID: 84899156240     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.April.17.11     Document Type: Article

References (13)

1. Banba N, Nakamura T, Matsumura M, Kuroda H, et al. (2000). Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 58: 684-690.
2. Ide Y, Matsui T, Ishibashi Y, Takeuchi M, et al. (2010). Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. Microvasc. Res. 80: 227-232.
3. Li J, Lim SS, Lee ES, Gong JH, et al. (2011). Isoangustone A suppresses mesangial fibrosis and inflammation in human renal mesangial cells. Exp. Biol. Med. 236: 435-444.
4. Ma DW, Wang QY, Ma XY, Li J, et al. (2011). The effect of fasudil via Rho/ROCK signaling pathway on the inflammation and fibrosis in human mesangial cells in high glucose medium. Zhonghua Nei Ke. Za Zhi 50: 580-584.
5. Mezzano S, Aros C, Droguett A, Burgos ME, et al. (2004). NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol. Dial. Transplant. 19: 2505-2512.
6. Min D, Lyons JG, Bonner J, Twigg SM, et al. (2009). Mesangial cell-derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 297: F1229-F1237.
7. Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, et al. (2011). Curcumin ameliorates macrophage infiltration by inhibiting NF-kappaB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr. Metab. 8: 35.
8. Tam FW, Riser BL, Meeran K, Rambow J, et al. (2009). Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 47: 37-42.
9. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, et al. (2003). Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 63: 209-216.
10. Wu J, Guan TJ, Zheng S, Grosjean F, et al. (2011). Inhibition of inflammation by pentosan polysulfate impedes the development and progression of severe diabetic nephropathy in aging C57B6 mice. Lab. Invest. 91: 1459-1471.
11. Wu X, Zha D, Xiang G, Zhang B, et al. (2006a). Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats. Cytokine 36: 229-236.
12. Wu Y, Dong J, Yuan L, Liang C, et al. (2008). Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy. Cytokine 44: 85-91.
13. Wu YG, Lin H, Qi XM, Wu GZ, et al. (2006b). Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int. Immunopharmacol. 6: 445-453.